Evidence map›Paper›PMID 39335615›Full record

ArticleBiomedicines2024

STAT3 Protein-Protein Interaction Analysis Finds P300 as a Regulator of STAT3 and Histone 3 Lysine 27 Acetylation in Pericytes.

Gautam Kundu, Maryam Ghasemi, Seungbin Yim, Ayanna Rohil, Cuiyan Xin, Leo Ren, Shraddha Srivastava, Akinwande Akinfolarin, Subodh Kumar, Gyan P Srivastava and 3 more

Abstract read
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Gautam KunduDivision of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Maryam GhasemiDivision of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Seungbin YimDivision of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Ayanna RohilDivision of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Cuiyan XinDivision of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.ORCID 0000-0002-5343-8554
Leo RenDivision of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Shraddha SrivastavaInstitute of Science, Banaras Hindu University, Varanasi 221005, India.
Akinwande AkinfolarinDivision of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Subodh KumarDepartment of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Gyan P SrivastavaDepartment of Electrical Engineering & Computer Science, University of Missouri, Columbia, MO 65211, USA.
Venkata S SabbisettiDivision of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Gopal MurugaiyanAnn Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Amrendra K AjayDivision of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.ORCID 0000-0003-2790-5726

Funding

Spatiotemporal delivery of synergistic drug combinations to kidney cancerR01CA229772 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI SABBISETTI, VENKATA · 2018 to 2022
$1.9M
American Heart Association 19CDA34780005NCI NIH HHS R01 CA229772
6 · The paper itself

Abstract

backgroundSignal transducer and activator of transcription 3 (STAT3) is a member of the cytoplasmic inducible transcription factors and plays an important role in mediating signals from cytokines, chemokines, and growth factors. We and others have found that STAT3 directly regulates pro-fibrotic signaling in the kidney. The STAT3 protein-protein interaction plays an important role in activating its transcriptional activity. It is necessary to identify these interactions to investigate their function in kidney disease. Here, we investigated the protein-protein interaction among three species to find crucial interactions that can be targeted to alleviate kidney disease.

methodIn this study, we examined common protein-protein interactions leading to the activation or downregulation of STAT3 among three different species: humans (

resultsUsing the STRING application from ExPASy, we found that six proteins, including PIAS3, JAK1, JAK2, EGFR, SRC, and EP300, showed highly confident interactions with STAT3 in humans, mice, and rabbits. We also found that IL-6 treatment increased the acetylation of STAT3 and increased histone 3 lysine acetylation (H3K27ac). Furthermore, we found that the disruption of STAT3 and P300 interaction by the P300 inhibitor A-485 decreased STAT3 acetylation and H3K27ac. Finally, we confirmed that the P300 inhibitor A-485 inhibited the binding of STAT3 with P300, which inhibited its transcriptional activity by reducing the expression of

conclusionsTargeting the P300 protein interaction with STAT3 may alleviate STAT3-mediated fibrotic signaling in humans and other species.

Indexed as

EGFREP300histone acetylationpericytesPIAS3protein–protein interactionSTAT3 acetylationSTRING

Identifiers

PMID39335615
PMCPMC11428717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.